Drug Profile

Lucatumumab

Alternative Names: CHIR-12.12; HCD-122

Latest Information Update: 17 Jul 2026

Price :

€55 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Novartis; XOMA
Class Antineoplastics; Monoclonal antibodies
Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen inhibitors; Immunomodulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Chronic lymphocytic leukaemia; Follicular lymphoma; Lymphoma; Multiple myeloma

Most Recent Events

14 Jul 2026 XOMA has been acquired by Ligand Pharmaceuticals
23 Jan 2013 Discontinued - Phase-I for Follicular lymphoma (combination therapy, second-line therapy or greater) in Belgium (IV)
23 Jan 2013 Discontinued - Phase-I for Follicular lymphoma (combination therapy, second-line therapy or greater) in USA (IV)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com